Moreover, in an exploratory analysis of grouping genes that were previously reported to predispose toward ER-positive disease, use of E + P MHT was modestly associated with high breast cancer risk in women with ATM or CHEK2 PVs. This evidence concerns the gene CHEK2 and breast cancer.